JP5238496B2 - 新規アミロイド親和性化合物 - Google Patents
新規アミロイド親和性化合物 Download PDFInfo
- Publication number
- JP5238496B2 JP5238496B2 JP2008516608A JP2008516608A JP5238496B2 JP 5238496 B2 JP5238496 B2 JP 5238496B2 JP 2008516608 A JP2008516608 A JP 2008516608A JP 2008516608 A JP2008516608 A JP 2008516608A JP 5238496 B2 JP5238496 B2 JP 5238496B2
- Authority
- JP
- Japan
- Prior art keywords
- pyridine
- compound
- mmol
- group
- amyloid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 239
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 74
- 230000002285 radioactive effect Effects 0.000 claims abstract description 58
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 46
- 239000000032 diagnostic agent Substances 0.000 claims abstract description 18
- 229940039227 diagnostic agent Drugs 0.000 claims abstract description 18
- 150000003839 salts Chemical class 0.000 claims abstract description 15
- 150000002367 halogens Chemical group 0.000 claims description 35
- -1 triphenylstannyl group Chemical group 0.000 claims description 23
- 208000024827 Alzheimer disease Diseases 0.000 claims description 20
- 125000001424 substituent group Chemical group 0.000 claims description 14
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 11
- 231100000053 low toxicity Toxicity 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 3
- 239000000460 chlorine Substances 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 2
- 125000005208 trialkylammonium group Chemical group 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 3
- 125000003638 stannyl group Chemical group [H][Sn]([H])([H])* 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract description 10
- 229910052757 nitrogen Inorganic materials 0.000 abstract description 5
- 231100000419 toxicity Toxicity 0.000 abstract description 4
- 230000001988 toxicity Effects 0.000 abstract description 4
- 125000005843 halogen group Chemical group 0.000 abstract 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 222
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 189
- 239000000243 solution Substances 0.000 description 158
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 150
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 118
- 238000006243 chemical reaction Methods 0.000 description 108
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 92
- 210000004556 brain Anatomy 0.000 description 91
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 84
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 68
- 239000000203 mixture Substances 0.000 description 68
- 238000003786 synthesis reaction Methods 0.000 description 65
- 230000015572 biosynthetic process Effects 0.000 description 64
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 63
- 230000002829 reductive effect Effects 0.000 description 59
- 239000002904 solvent Substances 0.000 description 58
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 55
- 239000000047 product Substances 0.000 description 54
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 51
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 51
- 239000002244 precipitate Substances 0.000 description 49
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 46
- 238000004128 high performance liquid chromatography Methods 0.000 description 42
- 239000000725 suspension Substances 0.000 description 42
- 238000005481 NMR spectroscopy Methods 0.000 description 41
- SDSBDQCXPSOHTP-UHFFFAOYSA-N 2-iodoimidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC(I)=CN21 SDSBDQCXPSOHTP-UHFFFAOYSA-N 0.000 description 38
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 38
- 238000009825 accumulation Methods 0.000 description 37
- LJYOFQHKEWTQRH-UHFFFAOYSA-N 2-bromo-1-(4-hydroxyphenyl)ethanone Chemical compound OC1=CC=C(C(=O)CBr)C=C1 LJYOFQHKEWTQRH-UHFFFAOYSA-N 0.000 description 36
- 239000003480 eluent Substances 0.000 description 35
- QTMDXZNDVAMKGV-UHFFFAOYSA-L copper(ii) bromide Chemical compound [Cu+2].[Br-].[Br-] QTMDXZNDVAMKGV-UHFFFAOYSA-L 0.000 description 34
- 239000012043 crude product Substances 0.000 description 34
- 239000011259 mixed solution Substances 0.000 description 34
- 239000012071 phase Substances 0.000 description 33
- 239000000126 substance Substances 0.000 description 33
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 description 32
- 238000010992 reflux Methods 0.000 description 32
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 31
- 238000000034 method Methods 0.000 description 31
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 30
- 238000010898 silica gel chromatography Methods 0.000 description 30
- 238000004809 thin layer chromatography Methods 0.000 description 30
- JADVWWSKYZXRGX-UHFFFAOYSA-M thioflavine T Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C1=[N+](C)C2=CC=C(C)C=C2S1 JADVWWSKYZXRGX-UHFFFAOYSA-M 0.000 description 30
- 239000012488 sample solution Substances 0.000 description 29
- 238000012360 testing method Methods 0.000 description 29
- 230000000052 comparative effect Effects 0.000 description 27
- 239000000523 sample Substances 0.000 description 27
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 26
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 26
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 26
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 23
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 21
- 241000700159 Rattus Species 0.000 description 21
- 238000011156 evaluation Methods 0.000 description 21
- 229910052740 iodine Inorganic materials 0.000 description 21
- 239000011630 iodine Substances 0.000 description 21
- 238000005259 measurement Methods 0.000 description 21
- 239000002504 physiological saline solution Substances 0.000 description 21
- 238000004458 analytical method Methods 0.000 description 19
- 238000003384 imaging method Methods 0.000 description 19
- 229910000027 potassium carbonate Inorganic materials 0.000 description 19
- 239000011541 reaction mixture Substances 0.000 description 19
- 238000005160 1H NMR spectroscopy Methods 0.000 description 18
- DJAPVDCXTHRTAM-UHFFFAOYSA-N 4-(6-bromoimidazo[1,2-a]pyridin-2-yl)phenol Chemical compound C1=CC(O)=CC=C1C1=CN(C=C(Br)C=C2)C2=N1 DJAPVDCXTHRTAM-UHFFFAOYSA-N 0.000 description 18
- 238000000211 autoradiogram Methods 0.000 description 18
- YBOCOHMLQZAQQZ-UHFFFAOYSA-N 4-(6-iodoimidazo[1,2-a]pyridin-2-yl)phenol Chemical compound C1=CC(O)=CC=C1C1=CN(C=C(I)C=C2)C2=N1 YBOCOHMLQZAQQZ-UHFFFAOYSA-N 0.000 description 17
- 229910021590 Copper(II) bromide Inorganic materials 0.000 description 17
- 230000027455 binding Effects 0.000 description 17
- 239000002243 precursor Substances 0.000 description 17
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 16
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
- 239000000706 filtrate Substances 0.000 description 16
- 238000010186 staining Methods 0.000 description 16
- 229960005070 ascorbic acid Drugs 0.000 description 15
- 235000010323 ascorbic acid Nutrition 0.000 description 15
- 239000011668 ascorbic acid Substances 0.000 description 15
- 230000008499 blood brain barrier function Effects 0.000 description 15
- 239000013078 crystal Substances 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 15
- 229910052736 halogen Inorganic materials 0.000 description 15
- 239000008363 phosphate buffer Substances 0.000 description 15
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 15
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- KPMVHELZNRNSMN-UHFFFAOYSA-N chembl1985849 Chemical compound N1=CC=C2NCCN21 KPMVHELZNRNSMN-UHFFFAOYSA-N 0.000 description 14
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 14
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 13
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 13
- 239000003365 glass fiber Substances 0.000 description 13
- 238000002372 labelling Methods 0.000 description 13
- 239000003208 petroleum Substances 0.000 description 13
- 239000007924 injection Substances 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 230000007886 mutagenicity Effects 0.000 description 12
- 231100000299 mutagenicity Toxicity 0.000 description 12
- 230000002194 synthesizing effect Effects 0.000 description 12
- WGOLHUGPTDEKCF-UHFFFAOYSA-N 5-bromopyridin-2-amine Chemical compound NC1=CC=C(Br)C=N1 WGOLHUGPTDEKCF-UHFFFAOYSA-N 0.000 description 11
- IVILGUFRMDBUEQ-UHFFFAOYSA-N 5-iodopyridin-2-amine Chemical compound NC1=CC=C(I)C=N1 IVILGUFRMDBUEQ-UHFFFAOYSA-N 0.000 description 11
- 238000001514 detection method Methods 0.000 description 11
- 239000000945 filler Substances 0.000 description 11
- 210000004940 nucleus Anatomy 0.000 description 11
- 230000002441 reversible effect Effects 0.000 description 11
- FVAUCKIRQBBSSJ-VVUPZWBASA-M sodium;iodine-123(1-) Chemical compound [Na+].[123I-] FVAUCKIRQBBSSJ-VVUPZWBASA-M 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- 239000000758 substrate Substances 0.000 description 11
- 239000003643 water by type Substances 0.000 description 11
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 10
- 241000700157 Rattus norvegicus Species 0.000 description 10
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 10
- 238000010191 image analysis Methods 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 9
- VNHWPVLQRKKKRY-UHFFFAOYSA-N 1-bromo-3-fluoropropane Chemical compound FCCCBr VNHWPVLQRKKKRY-UHFFFAOYSA-N 0.000 description 9
- 230000003197 catalytic effect Effects 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 239000013642 negative control Substances 0.000 description 9
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 9
- 238000002953 preparative HPLC Methods 0.000 description 9
- 229920006395 saturated elastomer Polymers 0.000 description 9
- 235000009518 sodium iodide Nutrition 0.000 description 9
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- DKFFAVRVYDPJBA-UHFFFAOYSA-N tributyl-[2-[4-(3-fluoropropoxy)phenyl]imidazo[1,2-a]pyridin-6-yl]stannane Chemical compound C=1N2C=C([Sn](CCCC)(CCCC)CCCC)C=CC2=NC=1C1=CC=C(OCCCF)C=C1 DKFFAVRVYDPJBA-UHFFFAOYSA-N 0.000 description 9
- 210000003462 vein Anatomy 0.000 description 9
- NPFKHHDTLDINMW-UHFFFAOYSA-N 2-[4-(6-tributylstannylimidazo[1,2-a]pyridin-2-yl)phenoxy]ethanol Chemical compound C=1N2C=C([Sn](CCCC)(CCCC)CCCC)C=CC2=NC=1C1=CC=C(OCCO)C=C1 NPFKHHDTLDINMW-UHFFFAOYSA-N 0.000 description 8
- YHHGLIPKAMQMBD-UHFFFAOYSA-N 6-bromo-2-[4-(3-fluoropropoxy)phenyl]imidazo[1,2-a]pyridine Chemical compound C1=CC(OCCCF)=CC=C1C1=CN(C=C(Br)C=C2)C2=N1 YHHGLIPKAMQMBD-UHFFFAOYSA-N 0.000 description 8
- 206010002091 Anaesthesia Diseases 0.000 description 8
- IUJDSEJGGMCXSG-UHFFFAOYSA-N Thiopental Chemical compound CCCC(C)C1(CC)C(=O)NC(=S)NC1=O IUJDSEJGGMCXSG-UHFFFAOYSA-N 0.000 description 8
- 230000037005 anaesthesia Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000005284 excitation Effects 0.000 description 8
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 8
- 238000005192 partition Methods 0.000 description 8
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 8
- 229960003279 thiopental Drugs 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 229940098773 bovine serum albumin Drugs 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 230000001575 pathological effect Effects 0.000 description 7
- 230000035699 permeability Effects 0.000 description 7
- 230000005855 radiation Effects 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- DQHMMQJBOXYOBS-UHFFFAOYSA-N 2-[4-(6-iodoimidazo[1,2-a]pyridin-2-yl)phenoxy]ethanol Chemical compound C1=CC(OCCO)=CC=C1C1=CN(C=C(I)C=C2)C2=N1 DQHMMQJBOXYOBS-UHFFFAOYSA-N 0.000 description 6
- WOTSEKGXOIGTRF-UHFFFAOYSA-N 2-bromoethoxy-tert-butyl-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](OCCBr)(C(C)(C)C)C1=CC=CC=C1 WOTSEKGXOIGTRF-UHFFFAOYSA-N 0.000 description 6
- PSDNWUFMRMFHDZ-UHFFFAOYSA-N 3-[4-(6-bromoimidazo[1,2-a]pyridin-2-yl)phenoxy]propyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCCCOC1=CC=C(C=2N=C3C=CC(Br)=CN3C=2)C=C1 PSDNWUFMRMFHDZ-UHFFFAOYSA-N 0.000 description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- 208000037259 Amyloid Plaque Diseases 0.000 description 6
- 235000010724 Wisteria floribunda Nutrition 0.000 description 6
- 210000004727 amygdala Anatomy 0.000 description 6
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 6
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 6
- 238000009826 distribution Methods 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 229940087646 methanolamine Drugs 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 239000007800 oxidant agent Substances 0.000 description 6
- 238000012856 packing Methods 0.000 description 6
- NGYZMMMCTJXETD-UHFFFAOYSA-N 2-[3-(6-iodoimidazo[1,2-a]pyridin-2-yl)phenoxy]ethanol Chemical compound OCCOC1=CC=CC(C=2N=C3C=CC(I)=CN3C=2)=C1 NGYZMMMCTJXETD-UHFFFAOYSA-N 0.000 description 5
- MNICSAISFYMXCH-UHFFFAOYSA-N 3-[4-(6-tributylstannylimidazo[1,2-a]pyridin-2-yl)phenoxy]propan-1-ol Chemical compound C=1N2C=C([Sn](CCCC)(CCCC)CCCC)C=CC2=NC=1C1=CC=C(OCCCO)C=C1 MNICSAISFYMXCH-UHFFFAOYSA-N 0.000 description 5
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 5
- GVPCWJLUMQDVKG-UHFFFAOYSA-N 6-bromo-2-[4-(2-fluoroethoxy)phenyl]imidazo[1,2-a]pyridine Chemical compound C1=CC(OCCF)=CC=C1C1=CN(C=C(Br)C=C2)C2=N1 GVPCWJLUMQDVKG-UHFFFAOYSA-N 0.000 description 5
- 208000031404 Chromosome Aberrations Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 238000004364 calculation method Methods 0.000 description 5
- 238000012790 confirmation Methods 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 238000013508 migration Methods 0.000 description 5
- 230000005012 migration Effects 0.000 description 5
- 238000009206 nuclear medicine Methods 0.000 description 5
- 239000008055 phosphate buffer solution Substances 0.000 description 5
- WTWGISIRNOHXHD-UHFFFAOYSA-N tributyl-[2-[4-(2-fluoroethoxy)phenyl]imidazo[1,2-a]pyridin-6-yl]stannane Chemical compound C=1N2C=C([Sn](CCCC)(CCCC)CCCC)C=CC2=NC=1C1=CC=C(OCCF)C=C1 WTWGISIRNOHXHD-UHFFFAOYSA-N 0.000 description 5
- JQTMFPPOPCINKJ-UHFFFAOYSA-N 2-(4-ethoxyphenyl)-6-iodoimidazo[1,2-a]pyridine Chemical compound C1=CC(OCC)=CC=C1C1=CN(C=C(I)C=C2)C2=N1 JQTMFPPOPCINKJ-UHFFFAOYSA-N 0.000 description 4
- OIPVFNYBOOVXSL-UHFFFAOYSA-N 2-[3-(6-tributylstannylimidazo[1,2-a]pyridin-2-yl)phenoxy]ethanol Chemical compound C=1N2C=C([Sn](CCCC)(CCCC)CCCC)C=CC2=NC=1C1=CC=CC(OCCO)=C1 OIPVFNYBOOVXSL-UHFFFAOYSA-N 0.000 description 4
- VXUPSLFKOTYIPR-UHFFFAOYSA-N 2-[4-(3-fluoropropoxy)phenyl]-6-iodoimidazo[1,2-a]pyridine Chemical compound C1=CC(OCCCF)=CC=C1C1=CN(C=C(I)C=C2)C2=N1 VXUPSLFKOTYIPR-UHFFFAOYSA-N 0.000 description 4
- QHYKPMKRSSTBJF-UHFFFAOYSA-N 2-[4-(3-fluoropropoxy)phenyl]-6-iodoimidazo[1,2-a]pyrimidine Chemical compound C1=CC(OCCCF)=CC=C1C1=CN(C=C(I)C=N2)C2=N1 QHYKPMKRSSTBJF-UHFFFAOYSA-N 0.000 description 4
- ZWHNFDKDABJADV-UHFFFAOYSA-N 3-[4-(6-bromoimidazo[1,2-a]pyridin-2-yl)phenoxy]propan-1-ol Chemical compound C1=CC(OCCCO)=CC=C1C1=CN(C=C(Br)C=C2)C2=N1 ZWHNFDKDABJADV-UHFFFAOYSA-N 0.000 description 4
- LHOLEEXIGAICPS-UHFFFAOYSA-N 3-[4-(6-iodoimidazo[1,2-a]pyridin-2-yl)phenoxy]propan-1-ol Chemical compound C1=CC(OCCCO)=CC=C1C1=CN(C=C(I)C=C2)C2=N1 LHOLEEXIGAICPS-UHFFFAOYSA-N 0.000 description 4
- LUJMEECXHPYQOF-UHFFFAOYSA-N 3-hydroxyacetophenone Chemical compound CC(=O)C1=CC=CC(O)=C1 LUJMEECXHPYQOF-UHFFFAOYSA-N 0.000 description 4
- ZWIARAQZLULYPG-NSCUHMNNSA-N 4-[(e)-2-[4-(methylamino)phenyl]ethenyl]phenol Chemical compound C1=CC(NC)=CC=C1\C=C\C1=CC=C(O)C=C1 ZWIARAQZLULYPG-NSCUHMNNSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 4
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 4
- 208000036632 Brain mass Diseases 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- ZCYVEMRRCGMTRW-AHCXROLUSA-N Iodine-123 Chemical compound [123I] ZCYVEMRRCGMTRW-AHCXROLUSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 4
- 230000005856 abnormality Effects 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 206010002022 amyloidosis Diseases 0.000 description 4
- 210000000702 aorta abdominal Anatomy 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 238000002224 dissection Methods 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 150000002431 hydrogen Chemical class 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 description 4
- PISQDQHXMQKKMZ-UHFFFAOYSA-N tributyl-[2-(4-ethoxyphenyl)imidazo[1,2-a]pyridin-6-yl]stannane Chemical compound C=1N2C=C([Sn](CCCC)(CCCC)CCCC)C=CC2=NC=1C1=CC=C(OCC)C=C1 PISQDQHXMQKKMZ-UHFFFAOYSA-N 0.000 description 4
- IAVCEBMLYVGBLA-UHFFFAOYSA-N 2-[1-[6-[2-fluoroethyl(methyl)amino]naphthalen-2-yl]ethylidene]propanedinitrile Chemical compound C1=C(C(C)=C(C#N)C#N)C=CC2=CC(N(CCF)C)=CC=C21 IAVCEBMLYVGBLA-UHFFFAOYSA-N 0.000 description 3
- PKFSXKBYBLYCAD-UHFFFAOYSA-N 2-[4-(2-fluoroethoxy)phenyl]-6-iodoimidazo[1,2-a]pyridine Chemical compound C1=CC(OCCF)=CC=C1C1=CN(C=C(I)C=C2)C2=N1 PKFSXKBYBLYCAD-UHFFFAOYSA-N 0.000 description 3
- KPSSTNXVRDDWRU-UHFFFAOYSA-N 2-[4-(6-bromoimidazo[1,2-a]pyridin-2-yl)phenoxy]ethyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCCOC1=CC=C(C=2N=C3C=CC(Br)=CN3C=2)C=C1 KPSSTNXVRDDWRU-UHFFFAOYSA-N 0.000 description 3
- LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 3
- RQFUZUMFPRMVDX-UHFFFAOYSA-N 3-Bromo-1-propanol Chemical compound OCCCBr RQFUZUMFPRMVDX-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-YYWVXINBSA-N DMF-d7 Substances [2H]C(=O)N(C([2H])([2H])[2H])C([2H])([2H])[2H] ZMXDDKWLCZADIW-YYWVXINBSA-N 0.000 description 3
- 206010012289 Dementia Diseases 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- KRHYYFGTRYWZRS-BJUDXGSMSA-N ac1l2y5h Chemical compound [18FH] KRHYYFGTRYWZRS-BJUDXGSMSA-N 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 231100000005 chromosome aberration Toxicity 0.000 description 3
- 230000003920 cognitive function Effects 0.000 description 3
- 238000002059 diagnostic imaging Methods 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- KRHYYFGTRYWZRS-BJUDXGSMSA-M fluorine-18(1-) Chemical compound [18F-] KRHYYFGTRYWZRS-BJUDXGSMSA-M 0.000 description 3
- 238000005558 fluorometry Methods 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000012332 laboratory investigation Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 238000012636 positron electron tomography Methods 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000009877 rendering Methods 0.000 description 3
- PJSWCLCQUIRIQP-UHFFFAOYSA-N tert-butyl-ethoxy-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](C(C)(C)C)(OCC)C1=CC=CC=C1 PJSWCLCQUIRIQP-UHFFFAOYSA-N 0.000 description 3
- IEPSGFQQGKPTPM-UHFFFAOYSA-N 2-bromo-1-(3-hydroxyphenyl)ethanone Chemical compound OC1=CC=CC(C(=O)CBr)=C1 IEPSGFQQGKPTPM-UHFFFAOYSA-N 0.000 description 2
- VJMIEHFULCHDLD-UHFFFAOYSA-N 2-bromo-1-(4-ethoxyphenyl)ethanone Chemical compound CCOC1=CC=C(C(=O)CBr)C=C1 VJMIEHFULCHDLD-UHFFFAOYSA-N 0.000 description 2
- XNRDLSNSMTUXBV-UHFFFAOYSA-N 2-fluoroethyl 4-methylbenzenesulfonate Chemical compound CC1=CC=C(S(=O)(=O)OCCF)C=C1 XNRDLSNSMTUXBV-UHFFFAOYSA-N 0.000 description 2
- DZVSAHOHDQUFMZ-UHFFFAOYSA-N 2-hydroxyethyl 4-methylbenzenesulfonate Chemical compound CC1=CC=C(S(=O)(=O)OCCO)C=C1 DZVSAHOHDQUFMZ-UHFFFAOYSA-N 0.000 description 2
- KHLHVBQTCLVQFL-UHFFFAOYSA-N 3-(6-iodoimidazo[1,2-a]pyridin-2-yl)phenol Chemical compound OC1=CC=CC(C=2N=C3C=CC(I)=CN3C=2)=C1 KHLHVBQTCLVQFL-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- WKRCOZSCENDENK-UHFFFAOYSA-N 4-(1,3-benzothiazol-2-yl)aniline Chemical compound C1=CC(N)=CC=C1C1=NC2=CC=CC=C2S1 WKRCOZSCENDENK-UHFFFAOYSA-N 0.000 description 2
- GLKDFGAOWZETRP-UHFFFAOYSA-N 4-(6-iodoimidazo[1,2-a]pyrimidin-2-yl)phenol Chemical compound C1=CC(O)=CC=C1C1=CN(C=C(I)C=N2)C2=N1 GLKDFGAOWZETRP-UHFFFAOYSA-N 0.000 description 2
- SZSBJKUORKLYBS-UHFFFAOYSA-N 4-(6-tributylstannylimidazo[1,2-a]pyridin-2-yl)phenol Chemical compound C=1N2C=C([Sn](CCCC)(CCCC)CCCC)C=CC2=NC=1C1=CC=C(O)C=C1 SZSBJKUORKLYBS-UHFFFAOYSA-N 0.000 description 2
- YHHGLIPKAMQMBD-SQZVAGKESA-N 6-bromo-2-[4-(3-(18F)fluoranylpropoxy)phenyl]imidazo[1,2-a]pyridine Chemical compound [18F]CCCOC1=CC=C(C=C1)C=1N=C2N(C=C(C=C2)Br)C=1 YHHGLIPKAMQMBD-SQZVAGKESA-N 0.000 description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 102000034240 fibrous proteins Human genes 0.000 description 2
- 108091005899 fibrous proteins Proteins 0.000 description 2
- 239000001307 helium Substances 0.000 description 2
- 229910052734 helium Inorganic materials 0.000 description 2
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- XMBWDFGMSWQBCA-RNFDNDRNSA-M iodine-131(1-) Chemical compound [131I-] XMBWDFGMSWQBCA-RNFDNDRNSA-M 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 2
- OEOPVJYUCSQVMJ-UHFFFAOYSA-N n,n-dimethyl-4-(6-methyl-1,3-benzothiazol-2-yl)aniline Chemical compound C1=CC(N(C)C)=CC=C1C1=NC2=CC=C(C)C=C2S1 OEOPVJYUCSQVMJ-UHFFFAOYSA-N 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- UQPUONNXJVWHRM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 UQPUONNXJVWHRM-UHFFFAOYSA-N 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- 239000003444 phase transfer catalyst Substances 0.000 description 2
- 238000012746 preparative thin layer chromatography Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 2
- 238000002603 single-photon emission computed tomography Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- FVAUCKIRQBBSSJ-FXMLPJBTSA-M sodium;iodine-125(1-) Chemical compound [Na+].[125I-] FVAUCKIRQBBSSJ-FXMLPJBTSA-M 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- ZDDWJBABLYQPRV-UHFFFAOYSA-N tert-butyl-[2-[4-(6-iodoimidazo[1,2-a]pyridin-2-yl)phenoxy]ethoxy]-diphenylsilane Chemical compound C=1C=C(C=2N=C3C=CC(I)=CN3C=2)C=CC=1OCCO[Si](C(C)(C)C)(C=1C=CC=CC=1)C1=CC=CC=C1 ZDDWJBABLYQPRV-UHFFFAOYSA-N 0.000 description 2
- KSDVKWDDTYEACX-UHFFFAOYSA-N tert-butyl-[3-[4-(6-iodoimidazo[1,2-a]pyridin-2-yl)phenoxy]propoxy]-dimethylsilane Chemical compound C1=CC(OCCCO[Si](C)(C)C(C)(C)C)=CC=C1C1=CN(C=C(I)C=C2)C2=N1 KSDVKWDDTYEACX-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 210000004885 white matter Anatomy 0.000 description 2
- LYAHJFZLDZDIOH-VURMDHGXSA-N (Z)-2-(2-furyl)-3-(5-nitro-2-furyl)acrylamide Chemical compound C=1C=COC=1/C(C(=O)N)=C/C1=CC=C([N+]([O-])=O)O1 LYAHJFZLDZDIOH-VURMDHGXSA-N 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical class C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- YJFNFQHMQJCPRG-UHFFFAOYSA-N 1-(4-ethoxyphenyl)ethanone Chemical compound CCOC1=CC=C(C(C)=O)C=C1 YJFNFQHMQJCPRG-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- ROMSXTLRDQOKOR-GKTGUEEDSA-N 2-[4-(6-(18F)fluoranylimidazo[1,2-a]pyridin-2-yl)phenoxy]ethanol Chemical compound [18F]C=1C=CC=2N(C=1)C=C(N=2)C1=CC=C(C=C1)OCCO ROMSXTLRDQOKOR-GKTGUEEDSA-N 0.000 description 1
- FEQHPJGNTRHJRX-UHFFFAOYSA-N 2-[4-(6-nitroimidazo[1,2-a]pyridin-2-yl)phenoxy]ethanol Chemical compound C1=CC(OCCO)=CC=C1C1=CN(C=C(C=C2)[N+]([O-])=O)C2=N1 FEQHPJGNTRHJRX-UHFFFAOYSA-N 0.000 description 1
- ZQAQXZBSGZUUNL-BJUDXGSMSA-N 2-[4-(methylamino)phenyl]-1,3-benzothiazol-6-ol Chemical compound C1=CC(N[11CH3])=CC=C1C1=NC2=CC=C(O)C=C2S1 ZQAQXZBSGZUUNL-BJUDXGSMSA-N 0.000 description 1
- ZQAQXZBSGZUUNL-UHFFFAOYSA-N 2-[4-(methylamino)phenyl]-1,3-benzothiazol-6-ol Chemical compound C1=CC(NC)=CC=C1C1=NC2=CC=C(O)C=C2S1 ZQAQXZBSGZUUNL-UHFFFAOYSA-N 0.000 description 1
- DBTWOTKWIVISQR-UHFFFAOYSA-N 2-bromopropan-1-ol Chemical compound CC(Br)CO DBTWOTKWIVISQR-UHFFFAOYSA-N 0.000 description 1
- FDRCIXUKBBBOPH-UHFFFAOYSA-N 2-ethenyl-1,3-benzoxazole Chemical class C1=CC=C2OC(C=C)=NC2=C1 FDRCIXUKBBBOPH-UHFFFAOYSA-N 0.000 description 1
- AUFVJZSDSXXFOI-UHFFFAOYSA-N 2.2.2-cryptand Chemical compound C1COCCOCCN2CCOCCOCCN1CCOCCOCC2 AUFVJZSDSXXFOI-UHFFFAOYSA-N 0.000 description 1
- RBCARPJOEUEZLS-UHFFFAOYSA-N 3-bromopyridin-2-amine Chemical compound NC1=NC=CC=C1Br RBCARPJOEUEZLS-UHFFFAOYSA-N 0.000 description 1
- UUDNBWSHTUFGDQ-UHFFFAOYSA-N 3-iodopyridin-2-amine Chemical group NC1=NC=CC=C1I UUDNBWSHTUFGDQ-UHFFFAOYSA-N 0.000 description 1
- UZZOZUQVHHJNTR-UHFFFAOYSA-N 4-(1,3-benzothiazol-2-yl)-2-iodoaniline Chemical compound C1=C(I)C(N)=CC=C1C1=NC2=CC=CC=C2S1 UZZOZUQVHHJNTR-UHFFFAOYSA-N 0.000 description 1
- FGQRNGPGBIJMET-UHFFFAOYSA-N 4-(6-iodo-1,3-benzothiazol-2-yl)-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=NC2=CC=C(I)C=C2S1 FGQRNGPGBIJMET-UHFFFAOYSA-N 0.000 description 1
- ZDGRIJNRIGFCGI-UHFFFAOYSA-N 4-(6-iodo-1,3-benzoxazol-2-yl)-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=NC2=CC=C(I)C=C2O1 ZDGRIJNRIGFCGI-UHFFFAOYSA-N 0.000 description 1
- AVSGPLPQWOQRLS-UHFFFAOYSA-N 4-(6-iodoimidazo[1,2-a]pyridin-2-yl)phenol;hydrobromide Chemical compound Br.C1=CC(O)=CC=C1C1=CN(C=C(I)C=C2)C2=N1 AVSGPLPQWOQRLS-UHFFFAOYSA-N 0.000 description 1
- RCVUDYJMEJWTNN-ONEGZZNKSA-N 4-[(e)-2-(4-iodophenyl)ethenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1\C=C\C1=CC=C(I)C=C1 RCVUDYJMEJWTNN-ONEGZZNKSA-N 0.000 description 1
- XTZDIUGVJZDRGY-UHFFFAOYSA-N 4-imidazo[1,2-a]pyridin-2-ylphenol Chemical compound C1=CC(O)=CC=C1C1=CN(C=CC=C2)C2=N1 XTZDIUGVJZDRGY-UHFFFAOYSA-N 0.000 description 1
- DDFHBQSCUXNBSA-UHFFFAOYSA-N 5-(5-carboxythiophen-2-yl)thiophene-2-carboxylic acid Chemical compound S1C(C(=O)O)=CC=C1C1=CC=C(C(O)=O)S1 DDFHBQSCUXNBSA-UHFFFAOYSA-N 0.000 description 1
- GSZMUPHKOPBPPS-UHFFFAOYSA-N 5-[2-[6-(2-fluoroethoxy)-1,3-benzoxazol-2-yl]ethenyl]-n,n-dimethyl-1,3-thiazol-2-amine Chemical compound S1C(N(C)C)=NC=C1C=CC1=NC2=CC=C(OCCF)C=C2O1 GSZMUPHKOPBPPS-UHFFFAOYSA-N 0.000 description 1
- VNHBYKHXBCYPBJ-UHFFFAOYSA-N 5-ethynylimidazo[1,2-a]pyridine Chemical compound C#CC1=CC=CC2=NC=CN12 VNHBYKHXBCYPBJ-UHFFFAOYSA-N 0.000 description 1
- HAFKCGZQRIIADX-UHFFFAOYSA-N 5-iodopyrimidin-2-amine Chemical compound NC1=NC=C(I)C=N1 HAFKCGZQRIIADX-UHFFFAOYSA-N 0.000 description 1
- ZYXOOFUOEJPQKM-UHFFFAOYSA-N 6-iodoimidazo[1,2-a]pyridine Chemical compound C1=C(I)C=CC2=NC=CN21 ZYXOOFUOEJPQKM-UHFFFAOYSA-N 0.000 description 1
- HWTDMFJYBAURQR-UHFFFAOYSA-N 80-82-0 Chemical compound OS(=O)(=O)C1=CC=CC=C1[N+]([O-])=O HWTDMFJYBAURQR-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 238000010953 Ames test Methods 0.000 description 1
- 231100000039 Ames test Toxicity 0.000 description 1
- 230000007082 Aβ accumulation Effects 0.000 description 1
- COYXAOYWWZWBCH-UHFFFAOYSA-N C1C(N=C2N1C=CC=C2)(C3=CC=C(C=C3)OCCCO)Br Chemical compound C1C(N=C2N1C=CC=C2)(C3=CC=C(C=C3)OCCCO)Br COYXAOYWWZWBCH-UHFFFAOYSA-N 0.000 description 1
- 0 CC(C)(C*)CC(C)(C)COCc(cc1)ccc1-c1c[n](****2)c2n1 Chemical compound CC(C)(C*)CC(C)(C)COCc(cc1)ccc1-c1c[n](****2)c2n1 0.000 description 1
- HRMJQILRZSMLAP-UHFFFAOYSA-N CC1=CC=C(C=C1)S(=O)(=O)OCCOC2=CC=C(C=C2)C3=C(N4C=CC=CC4=N3)Br Chemical compound CC1=CC=C(C=C1)S(=O)(=O)OCCOC2=CC=C(C=C2)C3=C(N4C=CC=CC4=N3)Br HRMJQILRZSMLAP-UHFFFAOYSA-N 0.000 description 1
- 206010008805 Chromosomal abnormalities Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 206010067477 Cytogenetic abnormality Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical group CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 238000012879 PET imaging Methods 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 208000020584 Polyploidy Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- GFZPUGCMGGUPHH-UHFFFAOYSA-N [I].[Na] Chemical compound [I].[Na] GFZPUGCMGGUPHH-UHFFFAOYSA-N 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 230000003941 amyloidogenesis Effects 0.000 description 1
- YCSBALJAGZKWFF-UHFFFAOYSA-N anthracen-2-amine Chemical compound C1=CC=CC2=CC3=CC(N)=CC=C3C=C21 YCSBALJAGZKWFF-UHFFFAOYSA-N 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000010533 azeotropic distillation Methods 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000000692 cap cell Anatomy 0.000 description 1
- YCITZMJNBYYMJO-UHFFFAOYSA-N chloro(diphenyl)silicon Chemical compound C=1C=CC=CC=1[Si](Cl)C1=CC=CC=C1 YCITZMJNBYYMJO-UHFFFAOYSA-N 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- UNXNGGMLCSMSLH-UHFFFAOYSA-N dihydrogen phosphate;triethylazanium Chemical compound OP(O)(O)=O.CCN(CC)CC UNXNGGMLCSMSLH-UHFFFAOYSA-N 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 150000005234 imidazo[1,2-a]pyridines Chemical class 0.000 description 1
- 150000005232 imidazopyridines Chemical class 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- QCAWEPFNJXQPAN-UHFFFAOYSA-N methoxyfenozide Chemical compound COC1=CC=CC(C(=O)NN(C(=O)C=2C=C(C)C=C(C)C=2)C(C)(C)C)=C1C QCAWEPFNJXQPAN-UHFFFAOYSA-N 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002790 naphthalenes Chemical class 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910001923 silver oxide Inorganic materials 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical class C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 150000001629 stilbenes Chemical class 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- CDCVXCLQQRIOOH-UHFFFAOYSA-N tert-butyl-[2-[3-(6-iodoimidazo[1,2-a]pyridin-2-yl)phenoxy]ethoxy]-diphenylsilane Chemical compound C=1C=CC(C=2N=C3C=CC(I)=CN3C=2)=CC=1OCCO[Si](C(C)(C)C)(C=1C=CC=CC=1)C1=CC=CC=C1 CDCVXCLQQRIOOH-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical group OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 229910052724 xenon Inorganic materials 0.000 description 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/22—Tin compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/22—Tin compounds
- C07F7/2208—Compounds having tin linked only to carbon, hydrogen and/or halogen
Description
このような脳内アミロイド画像診断用プローブの多くは、アミロイドに対する親和性が高く、かつ脳移行性の高い疎水性の低分子化合物を、種々の放射性核種、例えば11C、18F及び123I等で標識した化合物である。具体例として、6−ヨード−2−[4’−(N,N−ジメチルアミノ)フェニル]ベンゾチアゾール(以下、TZDMという)や6−ヒドロキシ−2−[4’−(N−メチルアミノ)フェニル]ベンゾチアゾール(以下、6−OH−BTA−1という)を始めとする種々のチオフラビン誘導体(特許文献1、非特許文献3)、(E)−4−メチルアミノ−4’―ヒドロキシスチルベン(以下、SB−13という)や(E)−4−ジメチルアミノ−4’―ヨードスチルベン(以下、m−I−SBという)を初めとするスチルベン化合物(特許文献2、非特許文献4、非特許文献5)、6−ヨード−2−[4’−(N,N−ジメチルアミノ)フェニル]ベンゾオキサゾール(以下、IBOXという)、6−[2−(フルオロ)エトキシ]−2−[2−(2−ジメチルアミノチアゾール−5−イル)エテニル]ベンゾオキサゾールを初めとするベンゾオキサゾール誘導体(非特許文献6,非特許文献7)、2−(1−{6−[(2−フルオロエチル)(メチル)アミノ]−2−ナフチル}エチリデン)マロノニトリル(以下、FDDNPという)を初めとするDDNP誘導体(特許文献4、非特許文献8)及び6−ヨード−2−[4’−(N,N−ジメチルアミノ)フェニル]イミダゾ[1,2−a]ピリジン(以下、IMPYという)を初めとするイミダゾピリジン誘導体(特許文献3、非特許文献9)等を11Cや放射性ハロゲンで標識した化合物が報告されている。さらに、これらの画像診断用プローブの一部については、ヒトイメージング研究が実施され、AD患者において健常例とは明らかに異なる脳への放射能集積を示すことが報告されている(非特許文献10、非特許文献11、非特許文献12、非特許文献13)。
TZDM、IBOX及びm−I−SBのヨードを[125I]で標識した化合物は、正常マウスを用いた実験の結果、投与後2分点において、いずれも脳内への移行が認められている。しかしこれらの化合物は、正常組織からのクリアランスが十分ではなく、投与後の時間経過に伴い、徐々に脳内に集積する傾向を示している(特表2005−512945号公報、Zhi-Ping Zhuang et al.,Nuclear Medicine and Biology, 2001, 28, p.887-894、H. F. Kung et al.,J. Am. Chem. Soc., 2001, 123, p.12740-12741)。正常組織からのクリアランスが十分でないと、アミロイド集積部位において十分なコントラストが得られないといった問題がある。SB−13を[11C]で標識した化合物については、ラットを用いた実験により正常組織からのクリアランスを有することが示されているが、そのクリアランス速度は十分に速いとはいえない(Masahiro Ono et al., Nuclear Medicine and Biology, 2003, 30, p.565-571)。
FDDNPについても、復帰突然変異試験にて陽性を示すことが、報告されている。(国際公開第03/106439号パンフレット)
また、IMPYにおいて、アミロイドが沈着していない白室等への非特異的な集積が見られることが、我々の検討の結果、確認されている(後述する比較例II-6参照)。AD診断剤として用いるためには、アミロイド沈着部位以外における非特異的な集積が抑えられた化合物を用いる必要があるが、そのような化合物はこれまで開示されていない。
また、mは0〜2の整数である。また、R1の結合部位は、炭素であるA3、すなわち、6位の炭素であることが好ましい。
また、nは0〜2の整数である。
R6は水素、水酸基、メトキシ基、カルボキシル基、アミノ基、N−メチルアミノ基、N,N−ジメチルアミノ基、及びシアノ基からなる群より選ばれる基である。R6は、好ましくは水素、水酸基、カルボキシル基又はアミノ基であり、より好ましくは水素又は水酸基であり、特に好ましくは水酸基である。
また、pは0〜2の整数である。
また、qは0〜2の整数である。
(放射性ハロゲン標識化合物の前駆体化合物の合成方法)
以下、6−トリブチルスタニル−2−[4’−(3”−フルオロプロポキシ)フェニル]イミダゾ[1,2−a]ピリジンを例にとり、本発明の一つの実施形態に係る、放射性ハロゲン標識化合物の前駆体化合物の合成方法を説明する。
次に、2−[4’−(3”−フルオロプロポキシ)フェニル]−6−[123I]ヨードイミダゾ[1,2−a]ピリジンを例にとり、本発明の別の一側面に係る、放射性ハロゲン標識化合物の製造方法について説明する。
酸化剤は、反応液中のヨウ素を酸化させることができるものであれば特に限定する必要はなく、好ましくは過酸化水素又は過酢酸を用いることができる。酸化剤の添加量は、反応溶液中のヨウ素を酸化させるのに十分な量であれば良い。
(放射性ハロゲン標識化合物の前駆体化合物の合成方法)
以下、6−トリブチルスタニル−2−[4’−(2”−ヒドロキシエトキシ)フェニル]イミダゾ[1,2−a]ピリジンを例にとり、本発明の一つの実施形態に係る、放射性ハロゲン標識化合物の前駆体化合物の合成方法を説明する。
次に、放射性ヨード標識体化合物を例にとり、本発明の別の一側面に係る、放射性ハロゲン標識化合物の製造方法について説明する。
酸化剤は、反応液中のヨウ素を酸化させることができるものであれば特に限定する必要はなく、好ましくは過酸化水素又は過酢酸を用いることができる。酸化剤の添加量は、反応溶液中のヨウ素を酸化させるのに十分な量であれば良い。
本発明に係る診断剤は、他の一般に知られている放射性診断剤と同様、本発明に係る放射性ハロゲン標識化合物を所望により適当なpHに調整された水又は生理食塩水、あるいはリンゲル液等に配合させた液として調製することができる。この場合における本化合物の濃度は、配合された本化合物の安定性が得られる濃度以下とする必要がある。本化合物の投与量は、投与された薬剤の分布を画像化するために十分な濃度であれば特に限定する必要はない。例えば、ヨウ素−123(123I)標識化合物及びフッ素−18(18F)標識化合物の場合は、体重60kgの成人一人当り50〜600MBq程度、静脈投与又は局所投与して使用することができる。投与された薬剤の分布は、公知の方法にて画像化することができ、例えばヨウ素−123(123I)標識化合物の場合はSPECT装置、フッ素−18(18F)標識化合物の場合はPET装置を用いて画像化することができる。
(実施例I)
下記実施例において、実験に供する各化合物の名称を、表1−1の様に定義した。
1H−NMR(溶媒:重クロロホルム、共鳴周波数:500MHz):δ8.01-7.93 ( m, 1H ), 7.91-7.87 ( m, 2H ), 7.75-7.74 ( m, 1H ), 7.63-7.58 ( m, 1H ), 7.20-7.11 ( m, 1H ), 7.00-6.95 ( m, 2H ), 4.67 ( dt, JHF = 47.0 Hz, J = 6.0 Hz, 2H ), 4.15 ( t, J = 6.0 Hz, 2H ), 2.20 ( dquint, JHF = 26.1 Hz, J = 6.0 Hz, 2H ), 1.64-1.47 ( m, 6H ), 1.39-1.31 ( m, 6H ), 1.19-1.04 ( m, 6H ), 0.91 ( t, J = 7.2 Hz, 9H )
カラム:Phenomenex Luna C18(商品名、Phenomenex社製、サイズ:4.6×150mm)
移動相:0.1%トリフルオロ酢酸/アセトニトリル=20/80→0/100(17分、直線グラジエント)
流速:1.0 mL/分
検出器:紫外可視吸光光度計(検出波長:282nm)及び放射線検出器 (形式:STEFFI型、raytest社製)
TLCプレート:RP−18F254(製品名、メルク社製)
展開相:メタノール/水=20/1
検出器:バイオイメージングアナライザー,BAS−2500(形式:BAS−2500、富士写真フィルム株式会社製)
1H−NMR(溶媒:重クロロホルム、共鳴周波数:500MHz):δ8.26-8.24 ( m, 1H ), 7.84-7.80 ( m, 2H ), 7.77-7.74 ( m, 2H ), 7.74 ( s, 1H ), 7.50 ( d, J = 9.7 Hz, 1H ), 7.26-7.23 ( m, 2H ), 7.21 ( dd, J = 9.7, 2.0 Hz, 1H ), 6.84-6.80 ( m, 2H ), 4.26 ( t, J = 6.0 Hz, 2H ), 3.98 ( t, J = 6.0 Hz, 2H ), 2.35 ( s, 3H ), 2.13 ( quint., J = 6.0 Hz, 2H ).
TLCプレート:Silica Gel 60 F254(製品名、メルク社製)
展開相:クロロホルム/メタノール/トリエチルアミン=500/10/0.5
検出器:Rita Star(製品名、raytest社製)
1H−NMR(溶媒:重ジメチルホルムアミド、共鳴周波数:500MHz):δ8.73-8.71 ( m, 1H ), 8.19-8.17 ( m, 1H ), 7.81-7.77 ( m, 2H ), 7.73-7.70 ( m, 2H ), 7.41-7.38 ( m, 1H ), 7.39-7.36 ( m, 2H ), 7.20 ( dd, J = 9.5, 1.9 Hz ), 6.85-6.81 ( m, 2H ), 4.34-4.31 ( m, 2H ), 4.19-4.15 ( m, 2H ).
1H−NMR(溶媒:重クロロホルム、共鳴周波数:500MHz):δ8.23 ( dd, J = 1.9, 0.2 Hz, 1H ), 7.88-7.83 ( m, 2H ), 7.51-7.48 ( m, 1H ), 8.21 ( dd, J = 9.5, 1.9 Hz, 1H ), 6.99-6.95 ( m, 2H ), 4.67 ( dt, 2JHF = 47.1 Hz, J = 5.9 Hz, 2H ), 4.15 ( t, J = 5.9 Hz, 2H ), 2.19 ( dquint, 3JHF = 25.9 Hz, J = 5.9 Hz, 2H )。
1H−NMR(溶媒:重クロロホルム、共鳴周波数:500MHz):δ8.37-8.35 ( m, 1H ), 7.88-7.84 ( m, 2H ), 7.72 ( s, 1H ), 7.42-7.39 ( m, 1H ), 7.32 ( dd, J = 9.4, 1.6 Hz, 1H ), 6.99-6.96 ( m, 2H ), 4.67 ( dt, 2JHF = 47.0 Hz, J = 6.0 Hz, 2H ), 4.15 ( t, J = 6.0 Hz, 2H ), 2.20 ( dquint, 3JHF = 25.9 Hz, J = 6.0 Hz, 2H )。
1H−NMR(溶媒:重クロロホルム、共鳴周波数:500MHz):δ8.23-8.21 ( m, 1H ), 7.87-7.84 ( m, 1H ), 7.72 ( s, 1H ), 7.51-7.47 ( m, 1H ), 7.20 ( dd, J = 9.5, 1.9 Hz, 1H ), 7.01-6.97 ( m, 2H ), 4.84-4.71 ( m, 2H ), 4.30-4.21 ( m, 2H )。
1H−NMR(溶媒:重クロロホルム、共鳴周波数:500MHz):δ8.35-8.33 ( m, 1H ), 7.88-7.84 ( m, 2H ), 7.70 ( s, 1H ), 7.39 ( d, J = 9.4 Hz, 1H ), 7.31 ( dd, J = 9.4, 1.8 Hz, 1H ), 7.01-6.97 ( m, 2H ), 4.84-4.71 ( m, 2H ), 4.30-4.22 ( m, 2H )。
1H−NMR(溶媒:重ジメチルスルホキシド、共鳴周波数:500MHz):δ9.27 ( d, J = 2.3 Hz, 1H ), 8.55 ( d, J = 2.3 Hz, 1H ), 8.15 ( s, 1H ), 7.94-7.90 ( m, 2H ), 7.06-7.02 ( m, 2H ), 4.62 ( dt, 2JHF = 47.2 Hz, J = 6.1, 2H ), 4.14 ( t, J = 6.1 Hz, 2H ), 2.13 ( dquint, 3JHF = 25.5 Hz, J = 6.1 Hz, 2H ).
1H−NMR(溶媒:重ジメチルスルホキシド、共鳴周波数:500MHz):δ8.86-8.84 ( m, 1H ), 8.14 ( s, 1H ), 7.78-7.74 ( m, 2H ), 7.40-7.35 ( m, 2H ), 6.86-6.82 ( m, 2H )。
以上の結果より、化合物I-6は高いアミロイド結合性を有することが示唆された。
本発明化合物のアミロイド親和性を、以下のin vitro結合試験により評価した。
カラム:Prodigy ODS(3)(製品名、phenomenex社製、サイズ:4.6×250 mm)
移動相:50mMトリエチルアミンりん酸(pH 7.2)/アセトニトリル=40/60混液
流速:0.7mL/分
検出器:紫外可視吸光光度計(検出波長:282nm)
各時間点において、実施例I-20及び比較例I-9については3匹、実施例I-21については2匹の動物を用いて実験を行った。
この結果より、化合物I-7は、脳内アミロイドに集積する性能を有し、脳内アミロイドの描出能を有することが示唆された。
1H−NMR(溶媒:重クロロホルム、共鳴周波数:500MHz): δ7.97 ( s, 1H ), 7.90 ( d, J = 8.7 Hz, 2H ), 7.58 ( d, J = 8.7 Hz, 1H ), 7.14 ( d, J = 8.7 Hz, 1H ), 6.99 ( d, J = 8.7 Hz, 2H ), 4.77 ( dt, J = 47.2, 4.1 Hz, 2H ), 3.99 ( dt, J = 28.0, 4.1 Hz, 2H ), 1.59-1.53( m, 6H ), 1.39-1.32 ( m, 6H ), 1.13-1.10 ( m, 6H ), 0.92 ( t, J = 7.3 Hz, 9H )。
TLCプレート:Silica Gel 60 F254(製品名、メルク社製)
展開相:クロロホルム/メタノール/トリエチルアミン=100/1/2
検出器:Rita Star(製品名、raytest社製)
なお、実験は、各時間点において、3匹の動物を用いて行った。
下記実施例において、実験に供する各化合物の名称を、表2−1の様に定義した。
1H−NMR(溶媒:重ジメチルスルホキシド、共鳴周波数:500MHz):δ8.95 ( s, 1H ), 8.27 ( s, 1H ), 7.87 ( d, J = 8.7 Hz, 2H), 7.54-7.46 ( m, 2H ), 7.04 (d, J = 8.7 Hz, 2H ), 4.04 ( t, J = 4.6 Hz, 2H ), 3.73 ( t, J = 4.6 Hz, 2H )。
1H−NMR(溶媒:重クロロホルム、共鳴周波数:500MHz):δ7.98 ( s, 1H ), 7.89 ( d, J = 8.7 Hz, 1H ), 7.75 ( s, 1H ), 7.56 ( d, J = 8.7 Hz, 1H ), 7.15 (d, J = 8.7 Hz, 1H ), 6.98 ( d, J = 8.7 Hz, 1H ), 4.13 ( t, J = 4.6 Hz, 2H ), 3.99 ( t, J = 4.6 Hz, 2H ), 2.63 ( s, 3H ), 1.64-1.51( m, 6H ), 1.36 ( sextet, J = 7.3 Hz, 6H ), 1.19-1.06 ( m, 6H ), 0.92 ( t, J = 7.3 Hz, 9H )。
カラム:Phenomenex Luna C18(商品名、Phenomenex社製、サイズ:4.6×150mm)
移動相:0.1%トリフルオロ酢酸/アセトニトリル=20/80→0/100(17分)
流速:1.0 mL/分
検出器:紫外可視吸光光度計(検出波長:282nm)及び放射線検出器(raytest社 STEFFI型)
TLCプレート:TLCプレート:Silica Gel 60 F254(製品名、メルク社製)
展開相:クロロホルム/メタノール/トリエチルアミン=100/1/2
検出器:Rita Star(製品名、raytest社製)
1H−NMR(溶媒:重ジメチルスルホキシド、共鳴周波数:500MHz):δ9.06 ( s, 1H ), 8.38 ( s, 1H ), 7.86 ( d, J = 8.7 Hz, 2H), 7.77-7.57 ( m, 2H ), 7.06 (d, J = 8.7 Hz, 2H ), 4.10 ( q, J = 6.9 Hz, 2H ), 1.36 ( t, J = 6.9 Hz, 3H )。
1H−NMR(溶媒:重クロロホルム、共鳴周波数:500MHz):δ7.96 ( s, 1H ), 7.88 ( d, J = 8.7 Hz, 2H), 7.74 ( s, 1H), 7.58 ( d, J = 8.7 Hz, 1H), 7.14 ( d, J = 8.7 Hz, 1H), 6.96 ( d, J = 8.7 Hz, 2H), 4.07 ( q, J = 6.9 Hz, 2H), 1.63-1.49 ( m, 6H), 1.43 ( t, J = 6.9 Hz, 3H), 1.39-1.31 ( m, 6H), 1.18-1.04 ( m, 6H ), 0.90( t, J = 7.3 Hz, 9H )。
カラム:Phenomenex Luna C18(商品名、Phenomenex社製、サイズ:4.6×150mm)
移動相:0.1%トリフルオロ酢酸/アセトニトリル=20/80→0/100(17分)
流速:1.0 mL/分
検出器:紫外可視吸光光度計(検出波長:282nm)及び放射線検出器 (raytest社 STEFFI型)
TLCプレート:TLCプレート:Silica Gel 60 F254(製品名、メルク社製)
展開相:クロロホルム/メタノール/トリエチルアミン=100/1/2
検出器:Rita Star(製品名、raytest社製)
本発明化合物のアミロイド親和性を、以下のin vitro結合試験により評価した。
なお、実験は、各時間点において、3匹の動物を用いて行った。
以上の結果より、化合物II-2は、脳内アミロイド描出における高い特異性を有する化合物であることが示された。
1H−NMR(溶媒:重ジメチルスルホキシド、共鳴周波数:500MHz):δ8.91 ( s, 1H ), 8.35 ( s, 1H ), 7.52-7.51 ( m, 2H ), 7.45 ( s, 2H ), 7.35 ( t, J = 8.2 Hz, 1H ), 6.93-6.90 ( m, 1H ), 4.06 ( t, J = 4.6 Hz, 2H ), 3.75 ( t, J = 4.6 Hz, 2H )。
1H−NMR(溶媒:重クロロホルム、共鳴周波数:500MHz):δ7.99 ( d, J = 0.9 Hz, 1H ), 7.82 ( s, 1H ), 7.64-7.50 ( m, 3H ), 7.34-7.31 ( m, 1H ), 7.18-7.17 ( m, 1H ), 6.90-6.87 ( m, 1H ), 4.20 ( t, J = 4.3 Hz, 2H ), 3.98 ( t, J = 4.3 Hz, 2H ), 1.69-1.48 ( m, 6H ), 1.39-1.32 ( m, 6H ), 1.19-1.05 ( m, 6H ), 0.91 ( t, J = 7.4 Hz, 9H )。
カラム:Phenomenex Luna C18(商品名、Phenomenex社製、サイズ:4.6×150mm)
移動相:0.1%トリフルオロ酢酸/アセトニトリル=20/80→0/100(17分)
流速:1.0 mL/分
検出器:紫外可視吸光光度計(検出波長:282nm)及び放射線検出器(raytest社 STEFFI型)
TLCプレート:TLCプレート:Silica Gel 60 F254(製品名、メルク社製)
展開相:クロロホルム/メタノール/トリエチルアミン=100/1/2
検出器:Rita Star(製品名、raytest社製)
1H−NMR(溶媒:重ジメチルホルムアミド、共鳴周波数:500MHz):δ8.96 ( s, 1H ), 8.33 ( s, 1H ), 7.98 ( d, J = 8.7 Hz, 2H ), 7.46 ( s, 2H ), 7.06 ( d, J = 8.7 Hz, 2H ), 4.63 ( t, J = 5.0 Hz, 1H ), 4.17 ( t, J = 6.0 Hz, 2H ), 3.72 ( dt, J = 5.0, 6.0 Hz, 2H ), 1.98 ( tt, J = 6.0, 6.0 Hz, 2H )。
1H−NMR(溶媒:重クロロホルム、共鳴周波数:500MHz):δ7.97 ( s, 1H ), 7.88 ( d, J = 8.3 Hz, 2H ), 7.74 ( s, 1H ), 7.58 ( d, J = 8.3 Hz, 1H ), 7.14 ( d, J = 8.7 Hz, 1H ), 6.98 ( d, J = 8.7 Hz, 2H ), 4.18 ( t, J = 6.0 Hz, 2H ), 3.89 ( t, J = 6.0 Hz, 2H ), 2.08 ( tt, J = 6.0, 6.0 Hz, 2H ), 1.59-1.49 ( m, 6H ), 1.39-1.31 ( m, 6H ), 1.18-1.05 ( m, 6H ), 0.90 ( t, J = 7.3 Hz, 9H )。
カラム:Phenomenex Luna C18(商品名、Phenomenex社製、サイズ:4.6×150mm)
移動相:0.1%トリフルオロ酢酸/アセトニトリル=20/80→0/100(17分)
流速:1.0 mL/分
検出器:紫外可視吸光光度計(検出波長:282nm)及び放射線検出器(raytest社 STEFFI型)
TLCプレート:Silica Gel 60 F254(製品名、メルク社製)
展開相:クロロホルム/メタノール/トリエチルアミン=100/1/2
検出器:Rita Star(製品名、raytest社製)
なお、実験は、各時間点において、3匹の動物を用いて行った。
Claims (13)
- R1が、18F、76Br、123I、124I、125I及び131Iからなる群より選択されたものである、請求項1に記載の化合物又はその塩。
- R2が、18F、76Br、123I、124I、125I及び131Iからなる群より選択されたものである、請求項1または2に記載の化合物又はその塩。
- R3が、塩素、ヨウ素、シュウ素、ニトロ置換基、トリメチルスタニル置換基、トリブチルスタニル置換基及びトリフェニルスタニル基からなる群より選択されたものである、請求項4に記載の化合物又はその塩。
- R1が、18F、76Br、123I、124I、125I及び131Iからなる群より選択されたものである、請求項6に記載の低毒性アルツハイマー病診断剤。
- R2が、18F、76Br、123I、124I、125I及び131Iからなる群より選択されたものである、請求項6または7に記載の低毒性アルツハイマー病診断剤。
- R5が、18F、76Br、123I、124I、125I及び131Iからなる群より選択されたものである、請求項9に記載の化合物又はその塩。
- R5が、18F、76Br、123I、124I、125I及び131Iからなる群より選択されたものである、請求項12に記載の低毒性アルツハイマー病診断剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008516608A JP5238496B2 (ja) | 2006-05-19 | 2007-05-15 | 新規アミロイド親和性化合物 |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006140044 | 2006-05-19 | ||
JP2006140044 | 2006-05-19 | ||
JP2006324701 | 2006-11-30 | ||
JP2006324701 | 2006-11-30 | ||
PCT/JP2007/059922 WO2007135890A1 (ja) | 2006-05-19 | 2007-05-15 | 新規アミロイド親和性化合物 |
JP2008516608A JP5238496B2 (ja) | 2006-05-19 | 2007-05-15 | 新規アミロイド親和性化合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2007135890A1 JPWO2007135890A1 (ja) | 2009-10-01 |
JP5238496B2 true JP5238496B2 (ja) | 2013-07-17 |
Family
ID=38723203
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008516608A Expired - Fee Related JP5238496B2 (ja) | 2006-05-19 | 2007-05-15 | 新規アミロイド親和性化合物 |
Country Status (15)
Country | Link |
---|---|
US (2) | US8303935B2 (ja) |
EP (1) | EP2019103B1 (ja) |
JP (1) | JP5238496B2 (ja) |
KR (1) | KR20090010987A (ja) |
AT (1) | ATE535527T1 (ja) |
AU (1) | AU2007252658B2 (ja) |
BR (1) | BRPI0711818A2 (ja) |
CA (1) | CA2653783A1 (ja) |
ES (1) | ES2376491T3 (ja) |
IL (4) | IL195378A0 (ja) |
NO (1) | NO20085265L (ja) |
NZ (1) | NZ573363A (ja) |
RU (1) | RU2008150377A (ja) |
TW (1) | TW200808795A (ja) |
WO (1) | WO2007135890A1 (ja) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200803903A (en) * | 2006-04-28 | 2008-01-16 | Nihon Mediphysics Co Ltd | Novel compound having affinity to amyloid |
EP2019103B1 (en) | 2006-05-19 | 2011-11-30 | Nihon Medi-Physics Co., Ltd. | Compound having affinity for amyloid |
EP2042501B1 (en) * | 2006-06-21 | 2017-04-12 | Nihon Medi-Physics Co., Ltd. | Compound having affinity for amyloid |
TW200811175A (en) * | 2006-06-21 | 2008-03-01 | Nihon Mediphysics Co Ltd | Novel compound with affinity with amyloid |
US20100056826A1 (en) * | 2006-11-09 | 2010-03-04 | Nihon Medi-Physicis Co., Ltd. | Radioactive diagnostic imaging agent |
WO2008059714A1 (fr) * | 2006-11-17 | 2008-05-22 | Nihon Medi-Physics Co., Ltd. | Composés inédits présentant une affinité pour la substance amyloïde |
US8207189B2 (en) | 2006-11-30 | 2012-06-26 | Nihon Medi-Physics Co., Ltd. | Compound having affinity for amyloid |
TWI406674B (zh) | 2007-02-13 | 2013-09-01 | Nihon Mediphysics Co Ltd | Method for manufacturing diagnostic radiographic diagnostic agents |
AU2008314870A1 (en) * | 2007-10-24 | 2009-04-30 | Nihon Medi-Physics Co., Ltd. | Novel compound having affinity for amyloid |
TW200918101A (en) | 2007-10-26 | 2009-05-01 | Nihon Mediphysics Co Ltd | Novel compound having affinity for amyloid |
WO2009057576A1 (ja) * | 2007-10-30 | 2009-05-07 | Nihon Medi-Physics Co., Ltd. | 新規アミロイド親和性化合物の使用及び製造方法 |
TW200922628A (en) * | 2007-10-30 | 2009-06-01 | Nihon Mediphysics Co Ltd | Use of novel compound having affinity for amyloid, and process for production of the same |
KR20100101577A (ko) * | 2007-10-30 | 2010-09-17 | 니혼 메디피직스 가부시키가이샤 | 신규 아밀로이드 친화성 화합물의 사용 및 제조 방법 |
EP2218464A1 (en) * | 2009-02-11 | 2010-08-18 | Technische Universität München | Compounds for non-invasive measurement of aggregates of amyloid peptides |
WO2011108236A1 (ja) * | 2010-03-01 | 2011-09-09 | 日本メジフィジックス株式会社 | 放射性ヨウ素標識有機化合物またはその塩 |
KR20140040722A (ko) * | 2011-05-20 | 2014-04-03 | 니혼 메디피직스 가부시키가이샤 | 신규 아밀로이드 친화성 화합물 |
ES2619830T3 (es) | 2011-06-24 | 2017-06-27 | Nihon Medi-Physics Co., Ltd. | Nuevo compuesto con afinidad por amiloide |
HUE033612T2 (en) | 2013-05-23 | 2017-12-28 | Hoffmann La Roche | 2-Phenylimidazo [1,2-a] pyrimidines as imaging agents |
SG11201908066XA (en) * | 2017-03-07 | 2019-09-27 | Nihon Mediphysics Co Ltd | Radioactive fluorine-labeled precursor compound, and method for producing radioactive fluorine-labeled compound using same |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6391391A (ja) * | 1986-09-22 | 1988-04-22 | オーソ・フアーマシユーチカル・コーポレーシヨン | 2−または3−アリール置換イミダゾ[1,2−a]ビリジン |
WO2001074813A2 (en) * | 2000-03-31 | 2001-10-11 | Ortho Mcneil Pharmaceutical, Inc. | METHOD FOR USING 2- OR 3-ARYL SUBSTITUTED IMIDAZO[1,2-a] PYRIDINES AS H3 ANTAGONISTS |
JP2004506633A (ja) * | 2000-08-16 | 2004-03-04 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | 新規β−アミロイド阻害剤、その製造方法及び医薬組成物としての使用 |
WO2005066177A1 (en) * | 2003-12-31 | 2005-07-21 | Schering-Plough Ltd. | Control of parasites in animals by the use of imidazo[1,2-b]pyridazine derivatives |
JP2005526749A (ja) * | 2002-03-06 | 2005-09-08 | ノバルティス アクチエンゲゼルシャフト | バイオマーカーとして有用なクマリン |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4871745A (en) | 1986-09-22 | 1989-10-03 | Ortho Pharmaceutical Corporation | 2- or 3-aryl substituted imidazo(1,2-A)pyridines and their use as antisecretory agents |
US4791117A (en) | 1986-09-22 | 1988-12-13 | Ortho Pharmaceutical Corporation | 2- or 3-aryl substituted imidazo[1,2-a]pyridines and their use as calcium channel blockers |
US4833149A (en) | 1986-09-22 | 1989-05-23 | Ortho Pharmaceutical Corporation | 2- or 3-aryl substituted imidazo[1,2-a]pyridines |
DE4327027A1 (de) | 1993-02-15 | 1994-08-18 | Bayer Ag | Imidazoazine |
NZ322674A (en) | 1995-10-17 | 1999-08-30 | Searle & Co | Method of detecting cyclooxygenase-2 |
US6812327B1 (en) | 1996-10-25 | 2004-11-02 | Human Genome Sciences, Inc. | Neutrokine-alpha polypeptides |
JP3980833B2 (ja) | 1998-08-20 | 2007-09-26 | リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア | βアミロイド斑及び神経原線維変化の標識方法 |
JP4025468B2 (ja) | 1999-07-29 | 2007-12-19 | 三井化学株式会社 | 有機電界発光素子 |
US20010051632A1 (en) | 2000-03-31 | 2001-12-13 | Wenying Chai | Phenyl-substituted indolizines and tetrahydroindolizines |
DE60128211T2 (de) | 2000-03-31 | 2008-01-10 | Ortho-Mcneil Pharmaceutical, Inc. | Phenyl-substituierte imidazopyridine |
US6514969B2 (en) | 2000-08-16 | 2003-02-04 | Boehringer Ingelheim Pharma Kg | β-amyloid inhibitors, processes for preparing them, and their use in pharmaceutical compositions |
PT1334091E (pt) | 2000-08-24 | 2013-01-07 | Univ Pittsburgh | Derivados de tioflavina e seu uso no diagnóstico e terapia da doença de alzheimer |
US6713042B2 (en) | 2001-02-26 | 2004-03-30 | Bristol-Myers Squibb Pharma Company | Ascorbic acid analogs for metalloradiopharmaceuticals |
US6596731B2 (en) * | 2001-03-27 | 2003-07-22 | Hoffmann-La Roche Inc. | Substituted imidazo[1,2-A] pyridine derivatives |
EP1381604B1 (en) | 2001-04-23 | 2006-12-27 | The Trustees Of The University Of Pennsylvania | Amyloid plaque aggregation inhibitors and diagnostic imaging agents |
WO2003000689A1 (en) | 2001-06-21 | 2003-01-03 | Smithkline Beecham Corporation | Imidazo`1,2-a!pyridine derivatives for the prophylaxis and treatment of herpes viral infections |
CN1299777C (zh) | 2001-08-27 | 2007-02-14 | 宾夕法尼亚州大学理事会 | 茋衍生物及其用于结合和成像淀粉样蛋白斑的用途 |
WO2003106439A1 (ja) | 2002-06-12 | 2003-12-24 | 株式会社ビーエフ研究所 | アミロイド蓄積性疾患の画像診断プローブ化合物、老人斑/びまん性老人斑染色用化合物、ならびにアミロイド蓄積性疾患の治療薬 |
CA2496633A1 (en) * | 2002-08-30 | 2004-04-29 | Bf Research Institute, Inc. | Diagnostic probes and remedies for diseases with accumulation of prion protein, and stains for prion protein |
AU2002337926B8 (en) | 2002-11-05 | 2008-02-28 | Ion Beam Applications S.A. | Stabilization of radiopharmaceuticals labeled with 18-F |
TW200803903A (en) | 2006-04-28 | 2008-01-16 | Nihon Mediphysics Co Ltd | Novel compound having affinity to amyloid |
EP2019103B1 (en) | 2006-05-19 | 2011-11-30 | Nihon Medi-Physics Co., Ltd. | Compound having affinity for amyloid |
EP2042501B1 (en) | 2006-06-21 | 2017-04-12 | Nihon Medi-Physics Co., Ltd. | Compound having affinity for amyloid |
AU2008314870A1 (en) | 2007-10-24 | 2009-04-30 | Nihon Medi-Physics Co., Ltd. | Novel compound having affinity for amyloid |
TW200918101A (en) | 2007-10-26 | 2009-05-01 | Nihon Mediphysics Co Ltd | Novel compound having affinity for amyloid |
KR20100101577A (ko) | 2007-10-30 | 2010-09-17 | 니혼 메디피직스 가부시키가이샤 | 신규 아밀로이드 친화성 화합물의 사용 및 제조 방법 |
-
2007
- 2007-05-15 EP EP07743357A patent/EP2019103B1/en not_active Not-in-force
- 2007-05-15 AT AT07743357T patent/ATE535527T1/de active
- 2007-05-15 TW TW096117253A patent/TW200808795A/zh unknown
- 2007-05-15 RU RU2008150377/04A patent/RU2008150377A/ru not_active Application Discontinuation
- 2007-05-15 BR BRPI0711818-0A patent/BRPI0711818A2/pt not_active IP Right Cessation
- 2007-05-15 NZ NZ573363A patent/NZ573363A/en not_active IP Right Cessation
- 2007-05-15 CA CA002653783A patent/CA2653783A1/en not_active Abandoned
- 2007-05-15 AU AU2007252658A patent/AU2007252658B2/en not_active Expired - Fee Related
- 2007-05-15 KR KR1020087028172A patent/KR20090010987A/ko not_active Application Discontinuation
- 2007-05-15 WO PCT/JP2007/059922 patent/WO2007135890A1/ja active Application Filing
- 2007-05-15 ES ES07743357T patent/ES2376491T3/es active Active
- 2007-05-15 US US12/227,487 patent/US8303935B2/en not_active Expired - Fee Related
- 2007-05-15 JP JP2008516608A patent/JP5238496B2/ja not_active Expired - Fee Related
-
2008
- 2008-11-19 IL IL195378A patent/IL195378A0/en unknown
- 2008-12-16 NO NO20085265A patent/NO20085265L/no not_active Application Discontinuation
-
2010
- 2010-11-30 IL IL209651A patent/IL209651A0/en unknown
- 2010-11-30 IL IL209649A patent/IL209649A0/en unknown
- 2010-11-30 IL IL209650A patent/IL209650A0/en unknown
-
2012
- 2012-06-29 US US13/537,422 patent/US8506930B2/en not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6391391A (ja) * | 1986-09-22 | 1988-04-22 | オーソ・フアーマシユーチカル・コーポレーシヨン | 2−または3−アリール置換イミダゾ[1,2−a]ビリジン |
WO2001074813A2 (en) * | 2000-03-31 | 2001-10-11 | Ortho Mcneil Pharmaceutical, Inc. | METHOD FOR USING 2- OR 3-ARYL SUBSTITUTED IMIDAZO[1,2-a] PYRIDINES AS H3 ANTAGONISTS |
JP2004506633A (ja) * | 2000-08-16 | 2004-03-04 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | 新規β−アミロイド阻害剤、その製造方法及び医薬組成物としての使用 |
JP2005526749A (ja) * | 2002-03-06 | 2005-09-08 | ノバルティス アクチエンゲゼルシャフト | バイオマーカーとして有用なクマリン |
WO2005066177A1 (en) * | 2003-12-31 | 2005-07-21 | Schering-Plough Ltd. | Control of parasites in animals by the use of imidazo[1,2-b]pyridazine derivatives |
Also Published As
Publication number | Publication date |
---|---|
JPWO2007135890A1 (ja) | 2009-10-01 |
WO2007135890A1 (ja) | 2007-11-29 |
EP2019103A4 (en) | 2010-05-05 |
IL209650A0 (en) | 2011-02-28 |
ATE535527T1 (de) | 2011-12-15 |
EP2019103B1 (en) | 2011-11-30 |
US20120271053A1 (en) | 2012-10-25 |
AU2007252658A1 (en) | 2007-11-29 |
NZ573363A (en) | 2012-01-12 |
US8303935B2 (en) | 2012-11-06 |
US20090252679A1 (en) | 2009-10-08 |
ES2376491T3 (es) | 2012-03-14 |
BRPI0711818A2 (pt) | 2011-12-13 |
TW200808795A (en) | 2008-02-16 |
US8506930B2 (en) | 2013-08-13 |
IL209649A0 (en) | 2011-02-28 |
IL209651A0 (en) | 2011-02-28 |
CA2653783A1 (en) | 2007-11-29 |
AU2007252658B2 (en) | 2012-03-29 |
EP2019103A1 (en) | 2009-01-28 |
RU2008150377A (ru) | 2010-06-27 |
NO20085265L (no) | 2009-02-18 |
KR20090010987A (ko) | 2009-01-30 |
IL195378A0 (en) | 2011-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5238496B2 (ja) | 新規アミロイド親和性化合物 | |
JP5313158B2 (ja) | 新規アミロイド親和性化合物 | |
JP5048655B2 (ja) | 新規アミロイド親和性化合物 | |
JP5180838B2 (ja) | 新規アミロイド親和性化合物 | |
JPWO2009057578A1 (ja) | 新規アミロイド親和性化合物の使用及び製造方法 | |
KR20090025282A (ko) | 신규 아밀로이드 친화성 화합물 | |
JPWO2009054496A1 (ja) | 新規アミロイド親和性化合物 | |
JPWO2009057576A1 (ja) | 新規アミロイド親和性化合物の使用及び製造方法 | |
KR20090091287A (ko) | 신규 아밀로이드 친화성 화합물 | |
JPWO2009057575A1 (ja) | 新規アミロイド親和性化合物の使用及び製造方法 | |
JP5247442B2 (ja) | 新規アミロイド親和性化合物 | |
CN101466711A (zh) | 对淀粉状蛋白具有亲和性的新化合物 | |
JP2009120591A (ja) | 新規アミロイド親和性化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100402 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121030 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130104 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130319 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130401 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160405 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |